THERAPY DOSSIER · th-9aefa63e693b

Methylprednisolone suleptanate sodium (U67590A) compared with methylprednisolone sodium succinate (MPSS)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Preclinical/no trial
ChEMBL record: CHEMBL2106453 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: Medrosol; Methylprednisolone suleptanate; PNU-67590A; Promedrol; U-67590A
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 2681792 ↗1989Reported benefit

Comparison of two ester prodrugs of methylprednisolone on early neurologic recovery in a murine closed head injury model.

MouseTBIClosed-head / concussionCF-1MaleIntravenousU67590A 7.5 or 15.0 mg/kg produced significant improvement;…Within 5 min of injury

Model: 900 g-cm concussive closed head injury

Both methylprednisolone esters improved early neurological recovery after severe concussive head injury. U67590A was four to eight times more potent than MPSS, with equal maximal efficacy, indicating the ester moiety influences cerebroprotective potency.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…